Lysosomal storage diseases: Stem cell-based cell- and gene-therapy
- PMID: 24853878
- DOI: 10.3727/096368914X681946
Lysosomal storage diseases: Stem cell-based cell- and gene-therapy
Abstract
Lysosomal storage diseases (LSDs) are caused by inborn genetic defects and most affected babies show pathology in the CNS. LSDs are caused by a specific inherited enzyme deficiency that results in accumulation of substrates in the lysosomes, distension of the organelles and subsequent cellular malfunction. Currently, no effective treatment is available for most of the LSDs, because the blood?brain barrier bars entry of enzyme preparations into the brain. Treatment for LSDs can be divided into those address symptoms or those address cause. At present, successful treatments for the LSDs are enzyme replacement therapy (ERT) and cell therapy. ERT is most successful in Gaucher disease and has been approved for Fabry disease, and mucopolysaccharidosis I (MPS I). In addition, ERT for Pompe disease, MPS II, MPS VI and MPS VII has been planned and awaiting approval for treatment. Limitations in ERT include need for life-long treatment, development of antibodies, and inability to cross blood brain barrier (BBB) resulting in failure to halt disease progression in the brain. Transplantation of hematopoietic stem cells (HSCs), bone marrow stem cells (BMSCs) and umbilical cord blood-derived stem cells (UCBSCs) offer effective but limited efficacy for patients suffering from Krabbe disease, MPS VII and adrenal leukodystrophy but in other LSDs they are ineffective. Intracranial/intracerebral transplantation of genetically modified stem cells as enzyme delivery system could bypass the BBB effectively and ensure release of therapeutically beneficial amount of enzymes to affected CNS lesion sites. For this reason, stem cell-based gene therapy is the most effective treatment for LSDs. In mouse models of LSDs, genetically modified neural stem cells encoding enzyme genes effectively decreased lysosomal storage, reduced pathology and extended life span of animals. Cell-based gene therapies for LSDs bridge the application of ERT and gene therapy and are important direction to pursue in the future.
Similar articles
-
Enzyme replacement therapy for lysosomal storage diseases.Pediatr Endocrinol Rev. 2012 Oct;10 Suppl 1:26-34. Pediatr Endocrinol Rev. 2012. PMID: 23330243 Review.
-
Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.Adv Exp Med Biol. 2021;1347:135-162. doi: 10.1007/5584_2021_639. Adv Exp Med Biol. 2021. PMID: 33977438
-
Treatment of lysosomal storage diseases: recent patents and future strategies.Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):9-25. doi: 10.2174/1872214808666140115111350. Recent Pat Endocr Metab Immune Drug Discov. 2014. PMID: 24433521 Review.
-
Gene therapy for lysosomal storage diseases (LSDs) in large animal models.ILAR J. 2009;50(2):112-21. doi: 10.1093/ilar.50.2.112. ILAR J. 2009. PMID: 19293456 Free PMC article. Review.
-
Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.Biomed Res Int. 2020 Dec 4;2020:2408402. doi: 10.1155/2020/2408402. eCollection 2020. Biomed Res Int. 2020. PMID: 33344633 Free PMC article. Review.
Cited by
-
Increasing β-hexosaminidase A activity using genetically modified mesenchymal stem cells.Neural Regen Res. 2024 Jan;19(1):212-219. doi: 10.4103/1673-5374.375328. Neural Regen Res. 2024. PMID: 37488869 Free PMC article.
-
Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.J Neurosci Res. 2016 Nov;94(11):990-1006. doi: 10.1002/jnr.23873. J Neurosci Res. 2016. PMID: 27638584 Free PMC article. Review.
-
Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.Orphanet J Rare Dis. 2016 Apr 16;11:40. doi: 10.1186/s13023-016-0414-2. Orphanet J Rare Dis. 2016. PMID: 27083890 Free PMC article. Review.
-
Gene Therapy of Sphingolipid Metabolic Disorders.Int J Mol Sci. 2023 Feb 11;24(4):3627. doi: 10.3390/ijms24043627. Int J Mol Sci. 2023. PMID: 36835039 Free PMC article. Review.
-
Spinal parenchymal occupation by neural stem cells after subpial delivery in adult immunodeficient rats.Stem Cells Transl Med. 2020 Feb;9(2):177-188. doi: 10.1002/sctm.19-0156. Epub 2019 Dec 4. Stem Cells Transl Med. 2020. PMID: 31800978 Free PMC article.
LinkOut - more resources
Full Text Sources
Other Literature Sources